|
|
News Breaks | | | | February 27, 2013 | | 07:33 EDT |  | ATRS | Antares Pharma'a Otrexup NDA accepted by FDA
Antares Pharma announced that the New Drug Application for Otrexup, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the FDA indicating that the application is sufficiently complete to permit a substantive review. Otrexup is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis, poly-articular-course juvenile RA and psoriasis. The FDA has assigned a target date of October 14, ten months from the official NDA filing, to complete its review of the NDA. | |
|
News For ATRS From The Last 14 Days Check below for free stories on ATRS the last two weeks. |
|
|
| There are no results for ATRS |
|
|
|
|
|
|
